New data demonstrating the efficacy of Brainsway’s Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) has been presented at the Society of Biological Psychiatry (SOBP) Annual Scientific Meeting ( 14–16 May, Toronto, Canada).
The new data on the treatment of OCD will also be presented at the American Psychiatric Association (APA) Annual Meeting (16–20 May, Toronto, Canada).
Deep TMS is an outpatient therapy that utilises a coil to generate brief magnetic fields at an amplitude similar to that used in magnetic resonance imaging (MRI). The therapy was introduced to the USA by Brainsway for treatment of major depressive disorder (MDD) and has been used to treat more than 5,000 MDD patients in more than 70 US clinics, including Harvard University, Mount Sinai Medical School and UC San Diego Medical Center.
Brainsway’s Deep TMS therapy is cleared by the US Food and Drug Administration (FDA) for the treatment of MDD and additional Deep TMS coils are currently being evaluated for the treatment of other indications, including ADHD and OCD.
“The current treatments for OCD and ADHD are limited. As a result, many patients are living with distressing symptoms for which Deep TMS offers the hope of relief,” said Ronen Segal, chief operating officer of Brainsway. “The ability to treat these conditions by non-invasively stimulating deep structures of the brain is truly promising for patients who suffer from these disorders.”
Brainsway’s Deep TMS therapy is based on patents filed by the National Institutes of Health (NIH) and by Brainsway. Brainsway holds the exclusive license from the NIH for the patent and therapy.